Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 8/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.40 |
| ▸ | CDK1 | P06493 | 3/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.40 |
| ▸ | CDK9 | P50750 | 3/20 | 0.40 |
| ▸ | TTK | P33981 | 10/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.40 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | TYK2 | P29597 | 2/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.36 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13336309 | 0.91 | CHEK1 (0.44) | CDK2CCNE2CCNE1CCNB2CDK1 | |
| SCHEMBL13336284 | 0.90 | CDK2 (0.40) | CDK2CCNE2CCNE1CCNB2CDK1 | |
| SCHEMBL13336279 | 0.90 | AXL (0.41) | CDK2CCNE2CCNE1CCNB2CDK1 | |
| SCHEMBL13336307 | 0.88 | PDK2 (0.42) | CDK2CCNE2CCNE1CCNB2CDK1 | |
| SCHEMBL13336280 | 0.87 | CDK2 (0.39) | CDK2CCNE2CCNE1CCNB2CDK1 | |
| SCHEMBL13336175 | 0.82 | JAK1 (0.41) | CDK2CCNE2CCNE1CCNB2CDK1 | |
| SCHEMBL13336161 | 0.82 | MAP4K3 (0.42) | CDK2TTKCCNA2JAK1TYK2 | |
| SCHEMBL13336122 | 0.81 | CHEK1 (0.47) | JAK1TYK2JAK3JAK2AXL | |
| SCHEMBL13336283 | 0.79 | FGFR1 (0.40) | CDK2CCNE2CCNE1CCNB2CDK1 | |
| SCHEMBL13336128 | 0.79 | GSK3B (0.43) | CDK2CCNE2CCNE1CCNB2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| WO-2009153313-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | CDK2 11/4885CCNE2 747/4885CCNE1 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.